KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Change in Cash (2016 - 2025)

Historic Change in Cash for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$856.8 million.

  • Biogen's Change in Cash fell 21420.95% to -$856.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $531.6 million, marking a year-over-year decrease of 6183.23%. This contributed to the annual value of $531.6 million for FY2025, which is 6183.23% down from last year.
  • According to the latest figures from Q4 2025, Biogen's Change in Cash is -$856.8 million, which was down 21420.95% from $1.1 billion recorded in Q3 2025.
  • Biogen's 5-year Change in Cash high stood at $1.1 billion for Q3 2025, and its period low was -$1.3 billion during Q4 2023.
  • Moreover, its 5-year median value for Change in Cash was -$16.6 million (2021), whereas its average is $86.2 million.
  • Examining YoY changes over the last 5 years, Biogen's Change in Cash showed a top increase of 71859.27% in 2022 and a maximum decrease of 52292.44% in 2022.
  • Quarter analysis of 5 years shows Biogen's Change in Cash stood at $735.4 million in 2021, then tumbled by 143.99% to -$323.5 million in 2022, then crashed by 297.5% to -$1.3 billion in 2023, then skyrocketed by 158.34% to $750.2 million in 2024, then plummeted by 214.21% to -$856.8 million in 2025.
  • Its Change in Cash was -$856.8 million in Q4 2025, compared to $1.1 billion in Q3 2025 and $92.2 million in Q2 2025.